Page last updated: 2024-12-05

4-toluenesulfonic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-toluenesulfonic acid: RN given refers to parent cpd; other RNs in 9th CI Form Index [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

toluene-4-sulfonic acid : An arenesulfonic acid that is benzenesulfonic acid in which the hydrogen at position 4 is replaced by a methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6101
CHEMBL ID541253
CHEBI ID27849
SCHEMBL ID34
MeSH IDM0094094

Synonyms (181)

Synonym
AC-794
p-toluenesulphonic acid
CHEBI:27849 ,
tosylic acid
toluen-4-sulfonsaeure
kyselina p-toluenesulfonova
benzenesulfonic acid, 4-methyl-
p-toluenesulfonate
p-tolylsulfonic acid
methylbenzenesulfonic acid
wln: wsqr d1
p-toluolenesulfonic acid
ar-toluenesulfonic acid
4-toluenesulfonic acid
p-toluenesulfonic acid ,
toluene-p-sulfonate
toluene-4-sulfonic acid
eltesol
cyclophil p t s a
benzenesulfonic acid, methyl-
p-methylbenzenesulfonic acid
p-methylphenylsulfonic acid
tosic acid
4-methylbenzenesulfonic acid
toluenesulfonic acid
nsc2167
nsc-2167
p-toluene-sulfonic acid
para-toluene sulfonate
inchi=1/c7h8o3s/c1-6-2-4-7(5-3-6)11(8,9)10/h2-5h,1h3,(h,8,9,10
TSU ,
4-toluene-sulfonic acid
C06677
104-15-4
nsc167068
nsc-167068
DB03120
hsdb 2026
ai3-26478
k-cure 040
cyzac 4040
manro ptsa 65 e
toluenesulfonic acid (van)
manro ptsa 65 ls
einecs 203-180-0
tsa-mh
k-cure 1040
tsa-hp
toluene-4-sulphonic acid
nsc 167068
toluene sulfonic acid
manro ptsa 65 h
kyselina p-toluensulfonova [czech]
nacure 1040
brn 0472690
kyselina p-toluenesulfonova [czech]
NCIOPEN2_002932
NCIOPEN2_003096
CHEMBL541253 ,
T0267
bdbm50294029
A800907
NCGC00248146-02
NCGC00248146-01
para-toluenesulfonic acid
p-toluene sulfonic acid
unii-qgv5zg5741
kyselina p-toluensulfonova
4-11-00-00241 (beilstein handbook reference)
qgv5zg5741 ,
ec 203-180-0
NCGC00259913-01
tox21_202364
dtxcid406701
dtxsid0026701 ,
cas-104-15-4
2(or 4)-toluenesulphonic acid
AKOS008966288
FT-0648905
anastrozole impurity f [ep impurity]
taycatox-300
activator-100t3
p-toluenesulfonic acid [mi]
tsa-95
toluene sulfonic acid [inci]
cyzac-4040
pts-100
kc-1040
lisinopril impurity b [ep impurity]
ad-3302w
sultamicillin impurity b [ep impurity]
eltesol tsx
nacure-1040
dryer-900
p-toluenesulfonic acid [ep impurity]
tizanidine hydrochloride impurity i [ep impurity]
c-250
AM90497
SCHEMBL34
p- toluenesulfonic acid
p-toluenesuiphonic acid
toluene-p-sulphonic acid
p -toluenesulfonic acid
para-toluenesulphonic acid
tosoh
para-toluene-sulfonic acid
p-toluyl sulphonic acid
p-toluene sulfonicacid
p-toluenesulfonicacid
toluene p-sulphonic acid
4-methyl-benzene sulphonic acid
ts-oh
para toluene sulfonic acid
4-methylphenylsulphonic acid
p-toluene sulphonic acid
p-toluensulfonic acid
p-toluen sulfonic acid
4-sulphotoluene
4methylbenzenesulfonic acid
para toluenesulfonic acid
p-tolu-enesulfonic acid
tosicacid
rho-toluene sulfonic acid
p-toluene-sulphonic acid
4-methylbenzenesulphonic acid
rho-toluenesulfonic acid
para toluenesulphonic acid
4-methylbenzene-sulfonic acid
4-methyl benzene sulfonic acid
p-toluensulphonic acid
toluene p-sulfonic acid
4-toluene-sulphonic acid
para-toluene sulfonic acid
paratoluene sulfonic acid
4-methylbenzene sulfonic acid
4-toluene sulphonic acid
tos-oh
p-toluene-sulfonicacid
p-tsoh
p-toluenesufonic acid
paratoluene sulphonic acid
4-methylbenzene-1-sulfonic acid
paratoluensulfonic acid
4-toluenesulphonic acid
paratoluenesulphonic acid
para-toluensulfonic acid
4-methylphenylsulfonic acid
para-toluene sulphonic acid
toluene 4-sulfonic acid
4-methyl-benzenesulfonic acid
toluene-p-sulfonic acid
4-methyl-benzene-sulphonic acid
para toluene sulphonic acid
ptsoh
paratoluene-sulfonic acid
4-toluenesulfinic acid sodium salt
Q-200514
p-toluene sulfonic acid(monohydrate)
J-001117
F1908-0079
AE-848/00887005
SR-01000944854-1
sr-01000944854
Q285878
CS-W019626
STL199173
NCGC00248146-03
paratoluenesulfonic acid
p-toluenylsulfonic acid
AT27303
BP-31081
AS-82150
4-toluenesulfonicacid
p-toluenesulfonic acid (ptsa)
SY011236
mfcd00064387
anastrozole impurity f (ep impurity)
p-toluenesulfonic acid (ep impurity)
sultamicillin impurity b (ep impurity)
tizanidine hydrochloride impurity i (ep impurity)
lisinopril impurity b (ep impurity)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Results of our study has proved the negative impact of ILs on the tested plants and the toxic effect of imidazolium salts was dependent primarily on the applied ionic liquids concentration."( The role of the anion in the toxicity of imidazolium ionic liquids.
Bałczewski, P; Biczak, R; Pawłowska, B; Rychter, P, 2014
)
0.4
" Taken together, these results emphasize the adverse effects of PPy/p-TSA on zebrafish development and behavior."( Adverse effects of p-TSA-doped polypyrrole particulate exposure during zebrafish (Danio rerio) development.
Basso, NRS; Bogo, MR; Corte, TWF; Costa, KM; Cruz, FF; Machado, P; Pereira, TCB; Pissinate, K; Soares, JC; Valente, CA, 2019
)
0.51
"Hypotension is the most common adverse event under propofol-mediated sedation and is possible to cause varying degrees of damage to patients."( The safety and efficacy of remimazolam tosylate combined with propofol in upper gastrointestinal endoscopy: A multicenter, randomized clinical trial.
Deng, Y; Dou, Y; Li, D; Liu, X; Ma, S; Wang, X; Wei, A; Wu, J; Yang, M; Zhou, S, 2023
)
0.91
" The safety results mainly include the incidence of Hypotension, adverse respiratory events, postoperative nausea and vomiting, hiccup, cough, body movement and bradycardia."( The safety and efficacy of remimazolam tosylate combined with propofol in upper gastrointestinal endoscopy: A multicenter, randomized clinical trial.
Deng, Y; Dou, Y; Li, D; Liu, X; Ma, S; Wang, X; Wei, A; Wu, J; Yang, M; Zhou, S, 2023
)
0.91
" The incidence of adverse events, in descending order, was P group, RT group, and R+P group (93."( The safety and efficacy of remimazolam tosylate combined with propofol in upper gastrointestinal endoscopy: A multicenter, randomized clinical trial.
Deng, Y; Dou, Y; Li, D; Liu, X; Ma, S; Wang, X; Wei, A; Wu, J; Yang, M; Zhou, S, 2023
)
0.91
"Co-administration had fewer adverse events than propofol monotherapy, also had a better sedative effect and higher endoscopist satisfaction than remimazolam monotherapy."( The safety and efficacy of remimazolam tosylate combined with propofol in upper gastrointestinal endoscopy: A multicenter, randomized clinical trial.
Deng, Y; Dou, Y; Li, D; Liu, X; Ma, S; Wang, X; Wei, A; Wu, J; Yang, M; Zhou, S, 2023
)
0.91
" When the sedation was successfully achieved, safety was evaluated based on the incidence of various intraoperative and postoperative adverse events."( Efficacy and Safety of Different Doses of Remimazolam Tosilate Applied in Upper Gastrointestinal Endoscopy: A Prospective Randomized Controlled Double-Blind Trial.
Cheng, Z; Cui, X; Li, H; Luan, H; Zhang, X; Zhao, Z; Zhu, P, 2023
)
0.91
" However, as the dose is progressively increased, the incidence of adverse reactions by remimazolam tosilate are also significantly increased, such as vertigo and prolonged sedation recovery time."( Efficacy and Safety of Different Doses of Remimazolam Tosilate Applied in Upper Gastrointestinal Endoscopy: A Prospective Randomized Controlled Double-Blind Trial.
Cheng, Z; Cui, X; Li, H; Luan, H; Zhang, X; Zhao, Z; Zhu, P, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" Pharmacokinetic and scintigraphic data from the first three dosing arms were used to select prototypes to be dosed in subsequent arms."( Optimization of LY545694 tosylate controlled release tablets through pharmacoscintigraphy.
Almaya, A; Argentine, MD; Connor, A; Lobo, ED; McDermott, J; Sperry, DC; Stevens, L, 2012
)
0.38
" This investigation focused on effects of various reaction conditions including solvent, acid catalyst, reaction temperature, residence time, water concentration, xylose loading and catalyst dosage on the dehydration of xylose to furfural."( Conversion of corn stalk into furfural using a novel heterogeneous strong acid catalyst in γ-valerolactone.
Chang, HM; Du, Z; Jameel, H; Li, W; Ma, L; Wu, H; Xu, Z, 2015
)
0.42
" These results indicate that the both the RBC Pig-a assay and PIGRET assay can detect in vivo IPTS mutagenicity under a single dosing protocol."( The rat Pig-a assay using an erythroid HIS49 antibody in a single dose study of isopropyl p-toluenesulfonate.
Chikura, S; Kaneko, H; Kasahara, Y; Kimoto, T; Miura, D; Okada, Y, 2016
)
0.43
" When water dosage was increased from 50 to 500 times of the WWS weight, the ash content gradually decreased during prewashing process, which facilitated lignin solubilization in subsequent p-toluenesulfonic acid (p-TsOH) hydrolysis."( Improving cellulose nanofibrillation of waste wheat straw using the combined methods of prewashing, p-toluenesulfonic acid hydrolysis, disk grinding, and endoglucanase post-treatment.
Bian, H; Dai, H; Fang, G; Gao, Y; Yang, Y, 2018
)
0.48
" Current study concludes prepared Hyperbranched cellulose nanofiber will be good alternative for commercially available dosage forms for the treatment of Alzheimer's diseases."( Hyperbranched cellulose polyester of oral thin film and nanofiber for rapid release of donepezil; preparation and in vivo evaluation.
AnjiReddy, K; Karpagam, S, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
toluenesAny member of the class of benzenes that is a substituted benzene in which the substituents include one (and only one) methyl group.
arenesulfonic acidOrganic derivatives of sulfonic acid in which the sulfo group is linked directly to carbon of an aryl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency27.33380.000657.913322,387.1992AID1259394
estrogen nuclear receptor alphaHomo sapiens (human)Potency55.02170.000229.305416,493.5996AID743075
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency19.95260.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 2Homo sapiens (human)Ki460.00000.00000.72369.9200AID421538
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID421538Binding affinity to human carbonic anhydrase 22009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Carbonic anhydrase-encoded dynamic constitutional libraries: toward the discovery of isozyme-specific inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (223)

TimeframeStudies, This Drug (%)All Drugs %
pre-199046 (20.63)18.7374
1990's12 (5.38)18.2507
2000's44 (19.73)29.6817
2010's101 (45.29)24.3611
2020's20 (8.97)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.39 (24.57)
Research Supply Index5.47 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index37.64 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.85%)5.53%
Reviews3 (1.28%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other230 (97.87%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]